Liver Transplantation for Hepatitis B Virus-Related Liver Disease

  • Steven B. Porter
  • K. Rajender Reddy
Conference paper


Globally, hepatitis B virus (HBV) infection is the single most common cause of cirrhosis although there is variability in the prevalence rate per geographic region. Currently hepatitis B accounts for approximately 4000-5000 deaths per year in the United States although far greater mortality is encountered in areas where HBV infection is endemic.


Orthotopic Liver Transplantation Adefovir Dipivoxil Hepatitis Delta Virus Cholestatic Hepatitis Lamivudine Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Magnius LO, Norder H. Subtypes, genotypes, and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995;38:24–34.PubMedGoogle Scholar
  2. 2.
    Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554–559.PubMedCrossRefGoogle Scholar
  3. 3.
    Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 1999;179:775–782.PubMedCrossRefGoogle Scholar
  4. 4.
    Tsubota A, Arase Y, Ren F, Tanaka H, Ikeda K, Kumada H. Genotype may correlate with liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepatitis B virus subtype adw. J Med Virol 2001;65:257–265.PubMedCrossRefGoogle Scholar
  5. 5.
    Hadziyannis SJ, Vassilopoulous D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617–624.PubMedCrossRefGoogle Scholar
  6. 6.
    Feray C, Gigou M, Samuel D, et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology 1993; 104:549–55.PubMedGoogle Scholar
  7. 7.
    Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prespective observation in 2215 patients. J Hepatol 1998;28:930–938.PubMedCrossRefGoogle Scholar
  8. 8.
    Chan HLY, Leung NWY, Hussain M, Wong ML, Lok ASF. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000;31:763–768.PubMedCrossRefGoogle Scholar
  9. 9.
    Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988;8:493–496.PubMedCrossRefGoogle Scholar
  10. 10.
    Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, Realdi G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991;32:294–298.CrossRefGoogle Scholar
  11. 11.
    Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989; 9:235–241.PubMedCrossRefGoogle Scholar
  12. 12.
    Realdi G, Fattovich G, Hadziyannis S, Schalm SW, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 1994;21:656–666.PubMedCrossRefGoogle Scholar
  13. 13.
    de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630–1635.PubMedGoogle Scholar
  14. 14.
    Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Mak is A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;2:588–591.PubMedCrossRefGoogle Scholar
  15. 15.
    Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. Hepatology 1995;21:77.PubMedGoogle Scholar
  16. 16.
    Fattovich G, Giustina G, Christensen E, Pantalena M, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 2000;46:420–426.PubMedCrossRefGoogle Scholar
  17. 17.
    Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus related liver disease. Hepatology 1991;13:619–26.PubMedGoogle Scholar
  18. 18.
    O’Grady JG, Smith HM, Davies, SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992;14:104–11.PubMedCrossRefGoogle Scholar
  19. 19.
    Lau JY, Bain VG, Davies SE, et al. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992;102:956–62.PubMedGoogle Scholar
  20. 20.
    Han S, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000;6:741–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Lok AS. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 2002;8:S67–73.PubMedCrossRefGoogle Scholar
  22. 22.
    al-Hemsi B, McGory R, Shepard B, et al. Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization. Clin Transplant 1996;10:668–75.PubMedGoogle Scholar
  23. 23.
    Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Devlin J, Smith H, O’Grady J, et al. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients. J Hepatol 1994;21:204–10.PubMedCrossRefGoogle Scholar
  25. 25.
    Gugenheim J, Crafa F, Fabiani P, et al. Long-term passive immunoprophylaxis of B virus recurrence after liver transplantation in HBs antigen-positive patients. Transpl Proc 1993;25:1349–50.Google Scholar
  26. 26.
    Konig V, Hopf U, Neuhaus P, et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994;58:553–9.PubMedCrossRefGoogle Scholar
  27. 27.
    McGory R, Ishitani M, Oliveira W, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996;61:1358–64.PubMedCrossRefGoogle Scholar
  28. 28.
    Muller R, Gubernatis G, Farle M, et al. Liver transplantation in HBs antigen (HBsAg) carriers: Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991;13:90–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Samuel D, Bismuth A, Mathieu D, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991;337:813–15.PubMedCrossRefGoogle Scholar
  30. 30.
    Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996;24:1327–33.PubMedCrossRefGoogle Scholar
  31. 31.
    Angus P, McCaughan G, Gane E, et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000;5:429–33.CrossRefGoogle Scholar
  32. 32.
    Villamil FG, Vierling JM. Recurrence of viral hepatitis after liver transplantation: insights into management. Liver Transpl Surg 1 1995;89–99.PubMedGoogle Scholar
  33. 33.
    Carman W, Trautwein C, van Deursen F, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996;24:489–93.PubMedCrossRefGoogle Scholar
  34. 34.
    Ghany M, Villamil F, Gish R, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998;27:213–22.PubMedCrossRefGoogle Scholar
  35. 35.
    Hawkins A, Gilson R, Gilbert N, et al. Hepatitis B virus surface mutations associated with infection after liver transplantation. J Hepatol 1996;24:8–14.PubMedCrossRefGoogle Scholar
  36. 36.
    Protzer-Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998;27:254–63.PubMedCrossRefGoogle Scholar
  37. 37.
    Terrault NA, Zhou S, McCory RW, et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998;28:555–61.PubMedCrossRefGoogle Scholar
  38. 38.
    Rosenberg PM, Dienstag JL. Therapy with nucleoside analogues for hepatitis B virus infection. Clin Liver Dis 1999;3(2):349–361.CrossRefGoogle Scholar
  39. 39.
    Fontana RJ, Keeffe EB, Carey W, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002;8:433–439.PubMedCrossRefGoogle Scholar
  40. 40.
    Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002;123:719–727.PubMedCrossRefGoogle Scholar
  41. 41.
    Yu AS, Keeffe EB: Liver Transplantation. In: Boyer T, Zakim D (eds). Hepatology: A Textbook of Liver Disease, 4th edition. Saunders, Philadelphia, pp. 2003;1617–1656.Google Scholar
  42. 42.
    Saab S, Kim M, Wright TL, et al. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology 2000;119:1382–1384.PubMedCrossRefGoogle Scholar
  43. 43.
    McCaughan GW, Spencer J, Koorey D, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999;5:512–519.PubMedCrossRefGoogle Scholar
  44. 44.
    Mutimer D, Feraz-Neto BH, Harrison R, et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 2001;49:860–863.PubMedCrossRefGoogle Scholar
  45. 45.
    Perrillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999;29:1581–1586.PubMedCrossRefGoogle Scholar
  46. 46.
    Walsh KM, Woodall T, Lamy P, et al. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001;49:436–440.PubMedCrossRefGoogle Scholar
  47. 47.
    Schiff ER, Neuhaus P, Tillmann H, et al. Safety and efficacy of adefovir dipivoxil for the treatment of lamivudine resistant HBV in patients post liver transplantation. Hepatology 2001;34(4 Pt 2):446A.Google Scholar
  48. 48.
    Genovesi EV, Lamb L, Medina I, et al. Efficacy of the carbocyclic 2’-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection [Abstract]. Antimicrob Agents Chemother 1998;42(12):3209–3217.PubMedGoogle Scholar
  49. 49.
    Aguesse-Germon S, Liu SH, Chevallier M, et al. Inhibitory effect of 2’-fluoro-5methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication. Antimicrob Agents Chemother 1998;42(2):369–376.PubMedGoogle Scholar
  50. 50.
    Marcellin P, Sereni D, Sacks S, et al. Anti-HBV activity and tolerability of clevudine, a novel nucleoside analogue: Initial results of a phase I/II 28-day study [Abstract]. Hepatology 2001;34(4 Pt 2):320A.CrossRefGoogle Scholar
  51. 51.
    Terrault NA, Vyas G. Hepatitis B immune globulin preparations and use in liver transplantation. Clinics in Liver Disease 2003 (in press).Google Scholar

Copyright information

© Springer Japan 2004

Authors and Affiliations

  • Steven B. Porter
    • 1
  • K. Rajender Reddy
    • 1
  1. 1.Medicine and SurgeryUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations